Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
Under the terms of the agreement, Otsuka is granted an exclusive license to develop, manufacture, and commercialize HBM7020, a BCMAxCD3 bispecific T-cell engager globally, excluding Greater China (Mainland China, Hong Kong, Macau and Taiwan). In return, Harbour BioMed will receive a total of $47 million in upfront and near-term payments. The company is also eligible for additional payments of up to $623 million upon the achievement of specified development and commercial milestones, as well as tiered royalties on future net sales. This strategic collaboration establishes a foundation for potential future partnerships between the two companies in the T-cell engager area.
'We are delighted to collaborate with Otsuka, a global healthcare leader renowned for its innovative approach to addressing unmet medical needs,' said Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed. 'This collaboration underscores the strength of Harbour BioMed's proprietary Harbour Mice® and HBICE® technology platforms, which enable the rapid development of fully human bispecific antibodies with optimized safety and efficacy profiles. By leveraging our unique capabilities, we are well-positioned to advance next-generation biotherapeutics that can make a meaningful difference in patients' lives worldwide.'
Makoto Inoue, President and Representative Director of Otsuka Pharmaceutical, noted, 'Otsuka is expanding our development pipeline in the autoimmune disease field by leveraging the antibody drug platform of our subsidiary Visterra, and the small molecule drug discovery platform of our subsidiary Jnana. HBM7020 is expected to demonstrate efficacy in a broad range of autoimmune diseases in which B cells play a major role in disease pathogenesis, and we hope to contribute further to the field of specialized autoimmune diseases and thereby benefit patients.'
About HBM7020
HBM7020 is a BCMAxCD3 bispecific antibody generated using Harbour BioMed's fully human HBICE® bispecific technology and Harbour Mice® platform. It is designed to crosslink target cells and T cells by binding to BCMA and CD3 on the cell surface, leading to potent T cell activation and targeted cell elimination. By incorporating dual anti-BCMA binding sites for enhanced cell targeting and monovalent-optimized CD3 activity to minimize cytokine release syndrome (CRS), HBM7020 has demonstrated potent cytotoxicity with broad therapeutic potential in both immunological and oncological diseases. In August 2023, HBM7020 obtained IND clearance from the National Medical Products Administration (NMPA) to commence a Phase I trial for cancer in China.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology. The company is building a robust and differentiated pipeline through internal R&D capabilities, strategic global collaborations in co-discovery and co-development, and selective acquisitions.
Harbour BioMed's proprietary antibody technology platform, Harbour Mice®, generates fully human monoclonal antibodies in both the conventional two heavy and two light chain (H2L2) format and the heavy chain-only (HCAb) format. Building upon HCAb antibodies, the HCAb-based immune cell engagers (HBICE®) bispecific antibody technology enables tumor-killing effects that traditional combination therapies cannot achieve. Additionally, the HCAb-based bispecific immune cell antagonist (HBICATM) technology empowers the development of innovative biologics for immunological and inflammatory diseases. By integrating Harbour Mice®, HBICE®, and HBICATM with a single B-cell cloning platform, Harbour BioMed has built a highly efficient and distinctive antibody discovery engine for developing next-generation therapeutic antibodies. For more information, please visit www.harbourbiomed.com .
About Otsuka Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd. is a total healthcare company that focuses on each individual's potential to enhance their well-being. Our medical-related business provides treatments and diagnostics for both physical and mental health. Our nutraceutical business supports daily health maintenance and improvement. Otsuka's unique products and services are based on scientific evidence, under the guidance of our corporate philosophy: Otsuka-people creating new products for better health worldwide.
For further information, please visit www.otsuka.co.jp/en/
View original content to download multimedia: https://www.prnewswire.com/news-releases/harbour-biomed-enters-global-strategic-collaboration-with-otsuka-to-advance-bcmaxcd3-bispecific-t-cell-engagers-302487815.html
SOURCE Harbour BioMed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
2 hours ago
- Bloomberg
Robots Emerge as New Driver for China's Tech Rally With 75% Jump
Chinese robotics stocks are drawing fresh market attention as investors look for new catalysts for the rally sparked earlier this year by DeepSeek's advances in artificial intelligence. The Solactive China Humanoid Robotics Index has surged about 75% over the past year, quadrupling the gain in the CSI 300 Index. Dazzling performances by robots at a conference in Shanghai last weekend and the launch of a humanoid for under $6,000 are among the latest sources of enthusiasm.
Yahoo
3 hours ago
- Yahoo
Moderna plans to slash 10% of workforce as COVID shot sales slow
Biotech company Moderna said Thursday it plans to cut 10% of its global workforce and expects to have fewer than 5,000 employees by the end of the year. The move is part of the company's ongoing effort to lower its annual operating expenses by around $1.5 billion by 2027, Moderna CEO Stéphane Bancel said Thursday in an internal letter to employees. Moderna has been relying on its new mRNA vaccines, including its experimental COVID-flu combination shot, to offset declining sales of its COVID-19 vaccine and respiratory syncytial virus vaccine, Reuters reported. Moderna Ceo Says Covid Moving Into Endemic Stage The company, based in Cambridge, Massachusetts, has made efforts to avoid job cuts, including scaling down research and development, lowering manufacturing expenses and renegotiating supplier contracts, Bancel said. "This decision was not made lightly," he said. "It impacts teammates and friends who have dedicated themselves to our mission and who have helped build Moderna. I want to express, on behalf of the entire Executive Committee and on behalf of patients you have served, our deepest thanks for everything you have contributed." Read On The Fox Business App Moderna Sues Pfizer, Biontech Over Covid Vaccine, Alleges Patent Infringement Earlier this year, the company estimated its annual operating costs for 2027 to be between $4.7 billion and $5 billion, according to Reuters. Moderna Looks To Inspire 'Revolution' In Cancer Treatments: Ceo The company's stock is down more than 90% from what it was during the COVID-19 pandemic, according to Reuters. In the letter, Bancel noted that Moderna has three approved products and could have as many as eight more product approvals in the next three years. He also said he would provide employees with more details about the layoffs at a company meeting Friday. "We are sharpening our focus, becoming leaner, and staying ambitious in oncology, rare diseases and latent viruses," Bancel said. Moderna did not immediately respond to FOX Business' request for article source: Moderna plans to slash 10% of workforce as COVID shot sales slow Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 hours ago
- Yahoo
CPP Investments to provide $225 million in funding for Ontario data center
TORONTO — CPP Investments says it will help fund an expansion to a data center project in Cambridge, Ont. The pension fund says it will invest $225 million in the project through a 50 per cent interest in a construction loan. Deutsche Bank Private Credit and Infrastructure will provide funding for the other half of the loan and will serve as the lead lender on the transaction. A press release from CPP Investments says there is strong demand for hyperscale data centers in Toronto and the surrounding areas. It says the project has been pre-leased on a long-term basis by an AI cloud computing provider. Geoffrey Souter, head of real assets credit, says the pension fund has deep expertise in the sector and the project will advance its global data center strategy. This report by The Canadian Press was first published July 31, 2025. The Canadian Press
